Key findings
- REPROCELL has launched StemEdit, a new set of clinical gene editing services and gene-edited induced pluripotent stem cell (iPSC) product lines.
- It OpenCRISPR-1, an AI-designed genome editing system licensed from Profluent.
- REPROCELL says StemEdit is built around GMP-aligned workflows and documentation aimed at clinical and regulatory use.
REPROCELL has launched StemEdit, a new set of clinical gene-editing services and gene-edited induced pluripotent stem cell (iPSC) product lines that use OpenCRISPR-1, an AI-designed genome-editing system licensed from Profluent.
What’s StemEdit?
StemEdit is REPROCELL’s advanced genome editing platform for iPSCs, which developers can use to kick-start gene-edited stem cell programs from early research to clinical development. It combines their StemRNA Clinical iPSC Seed Clones with OpenCRISPR-1-enabled engineering workflows.
What’s OpenCRISPR-1?
OpenCRISPR-1 is an open-source, AI-powered gene editing platform that allows for precise editing of the human genome from scratch. Profluent says this includes everything from precisely tuning existing CRISPR scaffolds to creating entirely novel editing systems. You can request access to OpenCRISPR here.
REPROCELL says the approach is GMP-aligned, traceable, ready for immediate use, and early reports are showing:
- high editing efficiency
- reduced off-target activity (unintended edits elsewhere in the genome)
- lower predicted immunogenicity (lower likelihood of triggering an immune response) in human cells
Intended use: allogeneic, off-the-shelf cell therapy development
StemEdit services and iPSC product lines are designed to support allogeneic (donor-derived) off-the-shelf cell therapy programs. The company positions the platform as offering targeting flexibility and a “licensing-friendly” alternative to more IP-encumbered CRISPR-Cas systems. The goal is to reduce intellectual property complexity and downstream commercial risk for therapy developers.
More information: www.reprocell.com
Want to keep up on regenerative medicine? Get the weekly newsletter here.
